Pfizer beats first quarter estimates on strong product growth

Pfizer beat Q1 expectations with adjusted EPS of $0.75 versus $0.72 consensus and revenue of $14.5 billion versus $13.84 billion expected. Ex-COVID product sales rose 7% operationally, led by Padcev (+39%), Eliquis (+8%), oncology biosimilars (+52%) and Nurtec (+41%), while COVID products continued to decline sharply. Pfizer reaffirmed 2026 guidance of $59.5 billion-$62.5 billion in revenue and $2.80-$3.00 in adjusted EPS; the midpoint EPS of $2.90 remains below the $2.96 analyst consensus.

Analysis

The immediate takeaway is not just that the quarter cleared the bar, but that the mix is finally shifting from “portfolio cleanup” to durable growth engines. That matters because the market has treated the name as a slow-execution, patent-cliff story; a consistent beat-plus-reaffirmation pattern can compress that discount even if top-line growth remains mid-single digits. The key second-order effect is valuation multiple support: when legacy cash cows are still shrinking, investors usually pay for pipeline optionality only after they see launched products compound for multiple quarters, and this print helps de-risk that transition.

The most important incremental signal is that growth is broadening outside the obvious blockbuster franchises, which reduces single-asset concentration risk and improves negotiating leverage in future BD/distribution discussions. In particular, ongoing strength in oncology and obesity should pull attention away from COVID-era drag and toward a longer-duration mix shift, which could improve gross margin quality if the company can maintain launch cadence without a step-up in SG&A. The market will likely focus on the below-consensus earnings midpoint, but that may be the wrong anchor: for large pharma, guide credibility and product-mix trajectory often matter more than a 2–3% EPS miss versus consensus.

The main risk is that this becomes a “good quarter, no new information” event if pipeline catalysts slip 1–2 quarters or if the current launch cohort matures faster than expected. Another risk is that an improving portfolio invites higher expectations without an immediate reset in free cash flow, especially if reinvestment intensity rises to defend the pipeline. On the other hand, if the obesity and oncology narratives keep compounding into the next two quarters, the stock can re-rate before full-year guidance is revised upward—equity investors usually move first on visibility, not realized earnings.

Key Decisions for Investors

• Go long PFE on 1–3 month horizon for a post-earnings drift trade; use a partial position on any intraday weakness, targeting a 5–8% re-rating if the market starts paying up for mix improvement rather than headline EPS.
• Pair trade: long PFE / short a basket of slower-growth large-cap pharma names with weaker launch momentum over the next 1–2 quarters; the thesis is relative multiple expansion for names with improving product cadence versus capital-markets skepticism around stalled pipelines.
• Buy PFE call spreads 3–6 months out to express upside from a second clean quarter while limiting premium bleed; structure around a modest move higher rather than a home-run pipeline scenario.
• If you already own PFE, hold through the next catalyst window but trail a stop under the post-earnings support level; the stock likely stays range-bound unless management can convert launch momentum into an upward guide reset.
• Do not chase aggressively above the post-print move until the next pipeline readout or guidance update; the risk/reward improves on pullbacks because the market is still pricing in execution skepticism.